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1. INTRODUCTION 
The neurophysin produced by vasopressinergic 
neurons of the ox has been called vasopressin- 
associated bovine neurophysin (VP-BNP) [l] and 
it has long been suspected that such neurophysins 
are initially translated as part of the prohormone 
structure of vasopressin [2,3,4; for reviews see 
5,6]. Some elegant work was recently performed to 
obtain the sequence of a cDNA encoding both 
vasopressin and its neurophysin from bovine 
hypothalamus [7]. This provided proof that both 
molecules arise as part of the same precursor. The 
primary structure of this precursor derived from a 
knowledge of the nucleotide sequence of an 
mRNA, places vasopressin on the N-terminal side 
of VP-BNP and joined to it by the tripeptide se- 
quence, -Gly-Lys-Arg-. A 39-residue glycopeptide 
is bridged to the C-terminus of VP-BNP by an 
Arg. On the N-terminal side of vasopressin there is 
a 19-residue peptide believed to represent the 
leader sequence of the translated prohormone. The 
prohormone (possibly minus the leader sequence) 
is believed to be processed within neurosecretory 
granules during transport from the perikarya of 
neurons to axonal storage sites in the neural lobe 
from where the products of intragranular proteo- 
lysis, vasopressin and VP-BNP, are released [5,6]. 
We have earlier demonstrated the presence in 
neurosecretory granules of an enzyme which might 
be involved in such a transformation [8]. Here we 
describe the characteristics of precursors to VP- 
BNP which were isolated from bovine neural 
lobes. These proteins provide us with a partial con- 
firmation of the structure derived for the prohor- 
mone from nucleotide sequencing, and also pro- 
vide information concerning the manner in which 
processing from prohormone to products might 
occur within the neurosecretory granules. 
2. MATERIALS AND METHODS 
Fresh frozen bovine neural lobes were extracted 
as in [9], in 0.1 M HCl at pH 1.5 in order to 
destroy proteolytic activity [lo]. Extracts were pro- 
cessed through 2.0 x 60 cm columns of Sephadex 
G-25 equilibrated with 1 .O M formic acid and the 
protein fraction was lyophilised. Protein was 
reconstituted in 10 mM ammonium acetate - 
0.15 M NaCl (pH 5.7) and passed through a 1.0 x 
10 cm column of Sepharose-bound Concanavalin 
A (ConA-Sepharose 4B, Sigma). The resin was 
washed with 5 column volumes of acetate, and 
bound material then eluted with concentrations of 
0.05 M and 0.5 M cY-methyl-D-mannoside in the 
10 mM acetate buffer. Material removed from the 
ConA-Sepharose by 0.05 M a-methyl-D- 
mannoside (-10 mg protein) was dialysed against 
4 changes of 100 volumes of 0.1 M acetic acid, 
lyophilised, reconstituted in 5 ml of 0.1 M acetic 
acid, and passed through a 1.2 x 60 cm column of 
Sephadex G-75 superfine. The eluant from this gel 
filtration was combined on the basis of absorbance 
at 280 nm to give 5 protein fractions. These frac- 
tions were represented by absorbance peaks having 
app. A4, of 65000, 30000, 17000, 10000 and 1000 
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by reference to the elution of bovine serum 
albumin, pepsin (pig), chymotrypsinogen (bovine), 
cytochrome c (emu) and vasopressin from such 
columns. Aliquots of each fraction were reduced 
and S-alkylated using N-ethylmaleimide [lo] and 
subjected to sodium dodecyl sulphate 
(SDS)-electrophoresis on 12.5% polyacrylamide 
[ 121 with 14C-labelled molecular markers purchas- 
ed from Amersham (CFA 626, CFA 645). The 
fraction from Sephadex which corresponded to the 
Mr range from 20000-12000 (app. M, of V,,,, 
17000) was found on SDS-electrophoresis to com- 
prise a single major protein component of M, 
16000 with about 10% contamination by proteins 
of M, 20000 and 12000. One-half of the protein in 
this fraction (0.5 mg) was reduced with 
2-mercaptoethanol (0.7 mmol) for 4 h and S- 
alkylated with 14C-labelled iodoacetamide 
(1.44 mmol, 0.17 mCi/ml) in the presence of 8 M 
urea at pH 8.6 as in [l]. The S-alkylated mixture 
was passed through a 1.0 x 60 cm column of 
Sephadex G-50 superfine wrapped in aluminum 
foil to eliminate light and the eluant monitored for 
14C. This chromatography clearly resolved 3 peaks 
of radioactivity in the protein region, 2 minor 
peaks on either side of a major peak. The major 
peak represented > 80% of the 14C counts and the 
protein in this peak which displayed a M, on 
SDS-electrophoresis of 16000 was used for further 
analysis. Some of this material (100 fig, -7 nmol) 
was hydrolysed in constant boiling HCl for 40 h at 
110°C and subjected to amino acid analysis on a 
Beckman 121MB amino acid analyzer. Another 
sample (300 fig, -20 nmol) was subjected to 
automated amino acid sequence analysis on a 
Beckman 890C Sequencer using a 0.1 M Quadrol 
buffer system [131. All PTH-amino acid were iden- 
tified by using high-pressure liquid chromato- 
graphy (HPLC) and 14C was counted in a Packard 
scintillation spectrometer, model 3255 (1). PTH- 
amino acid reference standards used were obtained 
from Sigma. HPLC was performed on a Beckman 
unit, model 332 plus model 1OOA pump, an 
Hitachi model 155-40 variable wavelength spectro- 
photometer with flow cell, and a model C-RIA 
Shimadzu Integrator-recorder. Automation in 
sample handling was possible through use of a 
WISP 710A automatic sample injector from 
Waters Associates. The remaining S-alkylated pro- 
tein (100 pg, -7 nmol) was subjected to digestion 
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with Carboxypeptidase Y (Pierce, 60 units/mg) at 
40°C for 15 min and 30 min using a substrate con- 
centration of 0.1 mM and an E/S molar ratio of 
1 :400 at pH 5.5. In each case the reaction was 
stopped by adding sulphosalicylic acid to a final 
concentration of 2.5%. Each sample was cen- 
trifuged at 10 000 x g for 2 min, the supernatants 
filtered through 0.22 micron filters, and then sub- 
jected to amino acid analysis using a 200 min 
lithium citrate physiological gradient on the 
Beckman 121MB analyzer. Control studies were 
performed with enzyme alone, and with VP-BNP 
as substrate. A small amount of non-modified pro- 
tein (-50 pg, -3 nmol) from the Sephadex G-75 
fraction was reacted with 3 x recrystalled 
cu-chymotrypsin (Worthington Biochemicals) at a 
substrate concentration of 0.1 mM and E/S molar 
ratio of 1: 100 for 4 h at 40°C and pH 7.6. The 
product was passed through a 1.5 x 2 cm column 
of ConA-Sepharose at pH 5.7 and bound material 
eluted as earlier described. This material was divid- 
ed into two fractions: one was hydrolysed in cons- 
tant boiling HCl for 40 h at 110°C and subjected 
to amino acid analysis, the other underwent partial 
sequencing on the 890C Beckman sequencer. 
3. RESULTS 
As judged by the criterion of SDS-electro- 
phoresis 13 proteins ranging from A4, > 65 000- > 
10000 were bound to ConA-Sepharose and 
displaced by a-methyl-D-mannoside (fig. 1). They 
were therefore, likely, glycoproteins. Sephadex 
G-75 filtration resolved these glycoproteins into 5 
fractions, one of which chiefly comprised (> 85%) 
a single species of M, 16000. Following 
S-carboxamidomethylation and filtration on 
Sephadex G-50, the major glycoprotein of this 
fraction appeared to be free of contaminants on 
SDS-electrophoresis. The amino acid analysis of 
the modified protein obtained from a single 40 h 
hydrolysis is shown in table 1 together with the 
amino acid composition of the proposed bovine 
precursor structure to vasopressin from residues 
1-147 [7]. Because of the compositional 
similarities, the calculations for residue number 
were based on a A4, of 14000 after removal of 2000 
for contribution of the carbohydrate moiety. The 
differences in amino acid composition might be ex- 
plained if the pituitary glycoprotein represented a
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Fig. 1. SDS-electrophoresis on 10% polyacrylamide of 
N-ethylmaleated proteins isolated from bovine neural 
lobes using ConA-affinity chromatography and elution 
with 50 mM cY-methyl-D-mannoside. Staining was 
performed with Coomassie Brilliant Blue. The positions 
of 14C-methylated reference proteins employed as 
internal M, markers are indicated: (a) cytochrome c; (b) 
lysozyme; (c) trypsin inhibitor; (d) carbonic anhydrase; 
(e) ovalbumin; (f) bovine serum albumin; (g) 
phosphorylase b. Also indicated is one major protein 
component of Mr 16000 which was purified and 
characterised. 
Table 1 
Amino acid aPLG bPro- ‘VP-BNP dGPP 
hormone 
CM-CYs 
(l/2 Cys) 
ASP 
Thr 
Ser 
Glu 
Pro 
Gly 
Ala 
Val 
Met 
Ile 
Leu 
Tyr 
Phe 
Lys 
His 
Arg 
15.4 16 14 _ 
12.5 10 5 1.5 
4.1 3 2 0.8 
8.7 8 6 2.0 
18.9 18 13 1.2 
11.5 14 I 0.7 
16.7 21 14 2.2 
9.5 13 6 1.0 
3.4 6 3 _ 
0.14 1 1 _ 
1.8 2 2 _ 
10.8 13 6 1.4 
1.4 3 1 - 
2.8 4 3 _ 
2.1 3 2 0.9 
0.65 0 0 _ 
1.9 12 I 1.1 
a Amino acid composition of a carboxamidomethylated 
posterior lobe glycoprotein(s) from 40-h acid 
hydrolysis 
b Amino acid composition of provasopressin (1-146) 
from the sequence derived in [7] 
’ Amino acid composition of VP-BNP from the 
sequence in [16] 
d Amino acid composition of the glycopeptide isolated 
following cr-chymotryptic digestion of PLG as 
determined from a 40-h acid hydrolysate 
truncated form of the proposed precursor struc- 
ture with an exception that the former appears to 
contain a single residue of histidine. 
Edman degradation of the modified glycopro- 
tein showed it to be > 90% represented by a single 
N-terminal sequence. This sequence was une- 
quivocally identified with the exception of one 
residue through 25 steps and is given in fig.2(a). It 
is identical to the N-terminal sequence of VP-BNP. 
Another sequence was present as a 5-10% con- 
tamination of the major protein, and is shown in 
fig.2(b). Some of the residues in this minor se- 
quence could not be identified because of overlap 
with the major sequence and noise from this struc- 
ture, but it appeared to commence with the se- 
quence of arginine vasopressin. This finding was 
31 
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(a) 
5 10 15 20 
Posterior Lobe Glycoprotein (major form) Ala-~let-Ser-Asp-Leu-Glu-Leu-Ar~-Gln-Cys-Leu-Pro-Cys-Gly-Pro-Gly-Gly-Lys-Gly-Ar~- 
VP-BNP Ala-Met-Ser-Asp-Leu-Glu-Leu-Arg-Gln-Cys-Leu-Pro-Cys-Gly-Pro-Gly-Gly-Lys-Gly-Ar~- 
25 
Posterior Lobe Glycoportein (major form) Cys-Phe-Gly-( )-Ser---------- 
VP-BNP Cys-Phe-Gly-Pro-Ser---------- - 
(b) 
5 10 
Posterior Lobe Glycoprotein (minor form) Cys-Tyr-Phe-Gin-(Asn)-Cys-Pro-(Arg)-(Cly)-( )---------- 
Arginine-Vasopressin Cys-Tyr-Phe-Gln- Asn -Cys-Pro- AI-~ - Gly - NH2 
Fig.2. Comparisons of (a) the amino-terminal sequences of a posterior lobe glycoprotein of I’$ 16000 and of vasopres- 
sin-associated bovine neurophysin, VP-BNP, showing sequence identity through 25 residues and (b) the amino-terminal 
sequence of a second posterior lobe glycoprotein present as a S-10% contaminant of the glycoprotein in (a) with the 
sequence of arginine-vasopressin showing sequence identity. ( ) indicates residues not clearly defined. 
supported by the pattern of 14C liberated from the 
preparation. The major peaks of radioactivity 
were at positions 10, 13 and 21 representing the 
neurophysin structure, but there were also present 
smaller peaks at positions 1, 6, 19 and possibly 22. 
Lu-Chymotryptic digestion of the unmodified 
protein preparation gave a product which bound to 
ConA and had the amino acid composition shown 
in table 1. The composition of this product is com- 
patible with it being portion(s) of the glycopeptide 
described in [14] which represents the C-terminal 
portion of the vasopressin/neurophysin precursor 
molecule described in [7]. Edman degradation of 
this glycopeptide (from digestion with LY- 
chymotrypsin) indicated that it possessed an N- 
terminal Ala. 
C-terminal analysis of VP-BNP using carboxy- 
peptidase Y gave the result shown in table 2a with 
the time-dependent liberation of Val, Arg, Phe and 
Pro, seemingly in that order. A substrate-free con- 
trol gave only a small peak in the position of Asn. 
The glycoprotein isolated from posterior 
pituitaries gave a liberation of amino acids shown 
in table 2b. Tyr, Leu, Val, Ala, Gly, Glu, Arg and 
Phe were all liberated. The large amount of Leu in- 
dicated that a number of Leu residues are near the 
C-terminus of the protein, but the patterns of 
liberation suggest the existence of two (or more) C- 
terminal structures, one possibly involving Tyr and 
Val, and also perhaps Phe, and the other involving 
Leu, Ala, Gly, Glu and Arg. 
32 
Table 2 
Carboxypeptidase Y digestions (4O”C, pH 5.5) of 
VP-BNP and a posterior lobe glycoprotein (PLG) for 
15 min and 30 min at an E/S molar ratio of 1: 400 and 
substrate concentration of 0.1 mM 
Residues/m01 
a. VP-BNP 
Pro 
Val 
Phe 
Arg 
15 min 30 min 
0.26 1.02 
0.97 0.99 
0.32 1.03 
0.47 2.04 
b. PLG 
Gln 
GIU 
GlY 
Ala 
Val 
Leu 
Tyr 
Phe 
Arg 
0.27 0.39 
0.82 1.50 
0.54 1.12 
0.60 1.18 
0.15 0.24 
1.60 2.57 
0.50 0.50 
0.12 0.35 
0.55 0.74 
4. DISCUSSION 
The mRNA sequence encoding a common 
precursor for vasopressin and VP-BNP has been 
used to deduce its amino acid sequence [7], but no 
Volume 152, number 1 FEBS LETTERS February 1983 
sequence information has been obtained directly 
on the isolated molecule. Also, the manner in 
which processing of the precursor takes place to 
liberate hormone and neurophysin within 
neurosecretory granules is not yet known. The data 
obtained here from sequencing and compositional 
analysis shows that the major proteins of a 
glycosylated preparation from bovine neural lobes 
are C-terminally elongated forms of VP-BNP. 
These glycoproteins of about M, 16000 represent 
most of the material in the Mr range 20000-14000. 
There appeared to be two such proteins with the N- 
terminal structure of VP-BNP. One of these had a 
C-terminal structure compatible with that of the 
proposed precursor, while the prevalent form con- 
tained a shortened glycopeptide that probably 
resulted from cleavage in the region of Leu129 of 
the precursor structure. We suggest the name ‘pro- 
neurophysins’ for these proteins to distinguish 
them from forms of the precursor that contain the 
structure of vasopressin, the prohormone and 
preprohormone. 
A single contaminant of the isolated proteins 
was shown by Edman degradation to have the 
structure of vasopressin at its N-terminus. Since 
this was present in the M, range of 20000-14000 
and was glycosylated, we believe it to be the 
vasopressin precursor (1-147) in [7], the 
prohormone. 
The presence of these molecules and their 
relative amounts in neural lobes suggests to us that 
the processing of prohormone within 
neurosecretory granules takes place according to 
the scheme illustrated in fig.3 with intermediate 
prohormone 
f 
1 
VP-BNP 
ptmeurophysin 
/ \9 
2’ 
/ 
IVP_BNP ~~ 
intact glycopeptide 
truncated proneumphysin 
A3 
truncated glycopeptideo 
Fig.3. A proposed scheme for the manner in which prohormone is processed to VP-BNP in vasopressinergic neurons 
of hypothalamic projections. The scheme is based on the presence and relative amounts of truncated ‘proneurophysin(s)‘, 
‘proneurophysin’, and prohormone in bovine neural lobes. The seemingly preferred route is: (1) the liberation of vaso- 
pressin and the bridging sequence (br) from the N-terminal structure of the prohormone to form ‘proneurophysin’; (2) 
the cleavage of a C-terminal fragment(s) from ‘proneurophysin’ to form a truncated ‘proneurophysin(s)‘; (3) the 
cleavage of the bridging sequence between VP-BNP and the shortened glycopeptide(s). As intact glycopeptide has also 
been located in bovine neural lobes [14], the direct conversion of ‘proneurophysin’ to VP-BNP and glycopeptide (step 
2’) must also occur. Such a scheme may not apply to processing by vasopressinergic neurons in extra-hypothalamic 
regions. 
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formation of ‘proneurophysins’ which lack the 
hormone sequence. The isolation of C-terminally 
truncated glycopeptides from bovine neural lobes 
[14] is further support for such a scheme. LY- 
Chymotrypsin seems to be capable of liberating 
glycopeptides from ‘proneurophysins’. 
Unfortunately, it was not clear in this study 
what sequences joined hormone to neurophysin 
and neurophysin to glycopeptide. Also, there are 
some questions raised by the data about the pro- 
posed structure of the vasopressin precursor. The 
presence of Lys and Phe in the composition of the 
glycopeptide is puzzling, and in this respect it is of 
interest that the glycopeptide of human neural 
lobes contains a Phe at position 22 [15]; there ap- 
pears to be a smaller amount of Leu than expected 
in the composition of our proneurophysins; and 
while the 14C peaks at positions 1, 6, 10, 13,21 and 
22 would be expected from N-terminal degradation 
of the mixture of the provasopressin and ‘pro- 
neurophysins’ obvious from HPLC, the ap- 
pearance of a 14C peak after 19 steps of Edman 
degradation is hard to reconcile with the published 
data on these sequences. 
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